Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

Most Angiotensin receptor blocker's (ARBs) are metabolized by cytochrome P4502C9 (CYP2C9), one of the major isoforms of the cytochrome P450 in human liver microsome. The purpose of this study is to evaluate whether CYP2C9 polymorphism has a significant clinical influence on the blood pressure lowering effect of losartan and valsartan. Weather there is a genetic importance in choosing the right ARB for the right patient.

Condition or disease	Intervention/treatment	Phase
Hypertension	Drug: losartan; Drug: valsartan	Not Applicable

  Show Detailed Description

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	30 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Official Title:	Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?
Study Start Date :	September 2008
Estimated Primary Completion Date :	September 2009

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: 1; Hypertensive patients will be treated with losartan for one months	Drug: losartan; with losartan 50 mg once daily for one month Drug: valsartan; valsartan 160 mg once daily
Experimental: 2; Hypertensive patients will be treated with valsartan	Drug: losartan; with losartan 50 mg once daily for one month Drug: valsartan; valsartan 160 mg once daily

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Blood pressure lowering effect of losartan and valsartan in patients with different CYP2C9 allels [ Time Frame: one month ]

Secondary Outcome Measures :

1. losartan/E-3174 ratio in different allelic groups of CYP2C9 [ Time Frame: one month ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• The study will include 30 patients with the 3 most prevalent alleles of CYP2C9 *1, *2 and*3, 10 patients of each group.

Exclusion Criteria:

• Patients treated with losartan or valsartan prior to their enrollment to the study,
• Patients with BP below 140 systolic or 90 diastolic in an ambulatory 24 hours BP monitoring, acute coronary syndrome during the 6 months previous to the study,
• Renal failure with creatinin levels above 1.5 mg/dL, hyperkalemia (K > 5 mg/dL),
• Hematologic or solid malignancies or pregnancy.

• Patients will also be excluded from the study if they are known to use one of the drugs inducing or inhibiting the CYP2C9, such as

  • rifampicin carbamazepine,
  • ethanol,
  • phenobarbitone,
  • fluconazole,
  • amiodarone,
  • trimethoprim,
  • fluvastatin,
  • cimetidine
  • chloramphenicol.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Contacts

Contact: Ronit Koren Peleg, MD	972-524-535024	ronitkoren@gmail.com
Contact: Ahuva Golik, Prof	972-577-345242	golik@asaf.health.gov.il

Sponsors and Collaborators

Assaf-Harofeh Medical Center

Investigators

Principal Investigator:	Ronit Koren Peleg, MD	Department of Internal Medicine A , Research & Development unit Assaf Harofeh Medical Center, Zerifin, affiliated to Sackler School of Medicine, Tel Aviv, Israel

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Koren Peleg Ronit MD, Assaf-Harofeh Medical Center internal medicine A
ClinicalTrials.gov Identifier:	NCT00732966 History of Changes
Other Study ID Numbers:	ronit3
First Posted:	August 12, 2008
Last Update Posted:	August 12, 2008
Last Verified:	August 2008

Keywords provided by Assaf-Harofeh Medical Center:

cyp2c9; losartan; pharmacogenetics; pharmacokinetics; pharmacodynamics

Additional relevant MeSH terms:

Valsartan; Losartan; Antihypertensive Agents; Angiotensin II Type 1 Receptor Blockers	Angiotensin Receptor Antagonists; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents